Literature DB >> 10991879

Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator.

P C Fuchs1, A L Barry, S D Brown.   

Abstract

Of 516 Staphylococcus aureus strains tested, 97.1% were susceptible to quinupristin-dalfopristin, which was bactericidal for 22 (56%) of the 39 strains tested, comparable to vancomycin. All 17 clindamycin and macrolide-resistant strains were inhibited but not killed by quinupristin-dalfopristin, whereas all 22 clindamycin-susceptible strains (5 were macrolide resistant) were killed.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10991879      PMCID： PMC90170          DOI： 10.1128/AAC.44.10.2880-2882.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci.

Authors:  G Lina; A Quaglia; M E Reverdy; R Leclercq; F Vandenesch; J Etienne
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  The in-vitro activity of RP 59500 against gram-positive cocci.

Authors:  S Goto; S Miyazaki; Y Kaneko
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

3.  In-vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci.

Authors:  J C Pechère
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

4.  RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci.

Authors:  G L Archer; P Auger; G V Doern; M J Ferraro; P C Fuchs; J H Jorgensen; D E Low; P R Murray; L B Reller; C W Stratton
Journal:  Diagn Microbiol Infect Dis       Date:  1993 Mar-Apr       Impact factor: 2.803

5.  In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

6.  The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination.

Authors:  H C Neu; N X Chin; J W Gu
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

7.  In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria.

Authors:  W Brumfitt; J M Hamilton-Miller; S Shah
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

8.  In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies.

Authors:  D J Hoban; B Weshnoweski; L Palatnick; C G Zhanel; R J Davidson
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

9.  Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.

Authors:  R Leclercq; L Nantas; C J Soussy; J Duval
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

10.  Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.

Authors:  B Fantin; R Leclercq; Y Merlé; L Saint-Julien; C Veyrat; J Duval; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191
View more
  7 in total

1.  Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Michael Schleimer; Jill Sauer; Anthony Man; Norman Nashed; Thomas Brown; Antonio Perez; Erhard Weidekamm; Péter Kovács
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Activity of a new oral streptogramin, XRP2868, against gram-positive cocci harboring various mechanisms of resistance to streptogramins.

Authors:  Michel Dupuis; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 3.  NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA.

Authors:  Amani D Politano; Robert G Sawyer
Journal:  Curr Opin Investig Drugs       Date:  2010-02

4.  Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  Community-associated methicillin-resistant Staphylococcus aureus: reconsideration of therapeutic options.

Authors:  Matthew E Levison; Shirley Fung
Journal:  Curr Infect Dis Rep       Date:  2006-01       Impact factor: 3.725

6.  Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Lars Nyman; Brigitte Roos; Michael Schleimer; Jill Sauer; Norman Nashed; Thomas Brown; Anthony Man; Erhard Weidekamm
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

7.  High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands.

Authors:  Arjanne Van Griethuysen; Annemarie Van 't Veen; Anton Buiting; Timothy Walsh; Jan Kluytmans
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.